1.	Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CR017479, 212082PCR3001, NCT01217697
2.	A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate Phase: Phase III Type: Treatment Status: Active Age: Any age Sponsor: Pharmaceutical / Industry Protocol IDs: CR100797, 212082PCR3010, 2011-005243-28, NCT01517802
3.	Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CR100011, ABI-PRO-3002, NCT01591122
4.	Abiraterone Acetate in Treating Postmenopausal Women With Advanced or Metastatic Breast Cancer Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CDR0000614059, CRUK-CR9304-21, EUDRACT-2007-003240-30, CR9304-21, NCT00755885
5.	A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Over 18 Sponsor: Pharmaceutical / Industry Protocol IDs: AT13387-04, NCT01685268
6.	Abiraterone Acetate, Prednisone, and Leuprolide Acetate or Goserelin Before and During Radiation Therapy in Treating Patients With Localized or Locally Advanced Prostate Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: 7048, NCI-2009-01346, NCT01023061
7.	Neo-adjuvant Abiraterone + Luteinizing Hormone-Releasing Hormone (LHRH) Versus LHRH in Prostate Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CR016945, COU-AA-203, NCT01088529
8.	Maximum Androgen Depletion Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2010-0070, NCT01254864
9.	Phase II Study of Abiraterone Acetate in Patients With Metastatic Prostate Cancer and a Sub-Optimal Prostate-Specific Antigen Following Initial Androgen-Deprivation Therapy Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: SWOG-S1014, S1014, NCT01309672
10.	IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CR017932, Protocol 212082PCR2005, NCT01314118
11.	A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CR018286, 212082BCA2001, 2011-000621-80, NCT01381874
12.	Abiraterone Acetate Combined With Dutasteride for Metastatic Castrate Resistant Prostate Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 10-448, NCT01393730
13.	A Study to Determine the Short-Term Safety of Continuous Dosing of Abiraterone Acetate and Prednisone in Modified Fasting and Fed States to Patients With Metastatic Castration-Resistant Prostate Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CR018715, 212082PCR2008, NCT01424930
14.	Study of GDC-0068 Or GDC-0980 With Abiraterone Acetate Versus Abiraterone Acetate in Patients With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Not specified Sponsor: Pharmaceutical / Industry Protocol IDs: GO27983, NCT01485861
15.	Concurrent Versus Sequential Treatment With Sipuleucel-T and Abiraterone in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC) Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: P11-3, NCT01487863
16.	Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: 18 and over Sponsor: NCI, Other Protocol IDs: 7639, NCI-2011-03745, NCT01503229
17.	Food Effect Study of Abiraterone Acetate for Treatment of Patients With Castration-Resistant Prostate Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Not specified Sponsor: NCI, Other Protocol IDs: 11-0709, NCI-2012-00116, NCT01543776
18.	AMG 386 and Abiraterone for Advanced Prostate Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: 120079, 12-C-0079, NCT01553188
19.	Phase II Randomized Study of Abiraterone Acetate With or Without Veliparib in Patients With Metastatic Castration-Resistant Prostate Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: UCCRC-IL057, IL057, 9012, NCT01576172
20.	A Phase II Study of Increased-Dose Abiraterone Acetate in Patients With Castration Resistant Prostate Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: UCSF Protocol No. 12551, NCT01637402
21.	A Study to Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Not specified Sponsor: Pharmaceutical / Industry Protocol IDs: 9785-CL-0011, NCT01650194
22.	Impact of the Addition of Metformin to Abiraterone in Metastatic Prostate Cancer Patients Phase: Phase II Type: Treatment Status: Approved-not yet active Age: 18 to 90 Sponsor: Other, Pharmaceutical / Industry Protocol IDs: MetAb-Pro, NCT01677897
23.	OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone Phase: Phase II Type: Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Other Protocol IDs: GU12-159, NCT01681433
24.	Abiraterone Acetate and Prednisone With or Without Dasatinib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: 4P-12-1, NCI-2012-01485, NCT01685125
25.	A Study of Abiraterone Acetate (JNJ-212082) and Prednisolone in Patients With Advanced Prostate Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CR100009, 212082PCR2007, NCT01685983